Diagnostic imaging devices are used for the visualization of structural and functional patterns of organs or tissues. A Nuclear Imaging agent is a compound, usually based on a drug molecule, that includes a small amount of radioactive material, or radiotracer. Radiotracers generate a signal that can be detected by a gamma (SPECT) camera or a positron emission tomography (PET) scanner. GlobalData uses proprietary data and analytics to provide a comprehensive report on the nuclear imaging agents market in Greece. Buy the latest report here.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
PET Imaging Agents includes Copper-Based PET Imaging Agents, Fluorine-Based PET Imaging Agents, Gallium-68-Based PET Imaging Agents and Rubidium-Based PET Imaging Agents. SPECT Imaging Agents includes Indium-Based SPECT Imaging Agents, Iodine-Based SPECT Imaging Agents, Lutetium-Based SPECT Imaging Agents, Technetium-Based SPECT Imaging Agents and Thallium-Based SPECT Imaging Agents.
The nuclear imaging agents market in Greece can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size nuclear imaging agents in Greece, buy the report here.